Location of Repository

The Regulation of Mammalian Target of Rapamycin

By Jianling Xie


mTOR is a highly conserved Serine/Threonine protein kinase which couples to a variety of stimulatory signals to control both anabolic and catabolic cellular processes. It exists in two biochemically and functionally distinct multi-component complexes termed as mTORC1 and mTORC2. Increasing evidence indicates that both mTOR complexes play crucial roles in the regulation of pancreatic β-cell function and mass. For example, hormones like GLP-1 that augment intracellular cAMP ([cAMP]i) are able to activate mTORC1 in β-cells, and it has been shown that GLP-1 treatment can lead to an enhancement of β-cell proliferation. However, in other cell types such as hepatocytes, neurons and many cancer cell lines, increases in [cAMP]i lead to the inhibition of mTORC1 which coincides with an impairment of cell replication. Therefore, the aims of this thesis were to reveal how cAMP regulates mTOR and to elucidate the molecular mechanism upon which mTOR complexes control pancreatic β-cell mass. My data provides evidence that the PKB-mTORC1 pathway by GLP-1 positively regulates β-cell proliferation, and that prolonged rapamycin treatment results in an induction of β-cell death which is caused by the inhibition of mTORC2 rather than mTORC1. These results further elucidated the mechanism by which mTOR complexes control pancreatic β-cell mass and therefore contribute to the design of future treatment against diabetes mellitus. \ud In addition, I have also shown that cAMP, in contrast to its effects in β-cells, inhibits both mTORC1 and 2 in mouse embryonic fibroblasts (MEFs) and human embryonic kidney (HEK293) cells by promoting complex dissociation and blocking mTOR kinase activity. Increases in [cAMP]i also inhibit protein synthesis and prevent cell cycle progression in MEFs. In conclusion, this work has further unravelled how mTOR complexes control pancreatic β-cell mass, and provided a rationale of using cAMP-inducing agents to treat cancer

Publisher: University of Leicester
Year: 2012
OAI identifier: oai:lra.le.ac.uk:2381/10948

Suggested articles



  1. (1998). 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Current biology :
  2. (1998). 4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family.
  3. (1998). 4EBP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway.
  4. (2008). A decrease in cellular energy status stimulates PERK-dependent eIF2alpha phosphorylation and regulates protein synthesis in pancreatic beta-cells.
  5. (2000). A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.
  6. (2012). A Dynamic Network Model of mTOR Signaling Reveals TSC-Independent mTORC2 Regulation. Science signaling 5,
  7. (2011). A FAK-PI-3K-mTOR axis is required for Wnt-Myc driven intestinal regeneration and tumorigenesis. Cell cycle (Georgetown,
  8. (2009). A gene network regulating lysosomal biogenesis and function.
  9. (2010). A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions.
  10. a homeostatic ATP sensor.
  11. (2012). A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB.
  12. (1994). A mammalian protein targeted by G1-arresting rapamycinreceptor complex.
  13. (2008). A novel Epac-Rap-PP2A signaling module controls cAMP-dependent Akt regulation.
  14. (2001). A novel method to identify protein kinase substrates: eEF2 kinase is phosphorylated and inhibited by SAPK4/p38delta.
  15. (2004). A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Molecular and cellular biology 24,
  16. (2001). A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.
  17. (2011). A phospho-proteomic screen identifies novel S6K1 and mTORC1 substrates revealing additional complexity in the signaling network regulating cell growth.
  18. (2003). A possible linkage between AMPactivated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes to cells : devoted to molecular & cellular mechanisms 8,
  19. (1995). A single ataxia telangiectasia gene with a product similar to PI-3 kinase.
  20. (2007). a target of S6K1 in nutrient- and obesity-induced insulin resistance.
  21. (2003). A unified nomenclature for yeast autophagy-related genes.
  22. (2006). Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.
  23. (2004). Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity.
  24. (2004). Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth.
  25. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators.
  26. (2010). Activation of a metabolic gene regulatory network downstream of mTOR complex 1.
  27. (1992). Activation of p70s6k is associated with phosphorylation of four clustered sites displaying Ser/ThrPro motifs.
  28. (2008). Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of
  29. (2005). Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). The Biochemical journal 388,
  30. (2003). Activation of S6K1 (p70 ribosomal protein S6 kinase 1) requires an initial calcium-dependent priming event involving formation of a high-molecular-mass signalling complex.
  31. (2001). Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1.
  32. Adrenaline potentiates insulin-stimulated PKB activation via cAMP and Epac: implications for cross talk between insulin and adrenaline.
  33. (2004). Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation.
  34. (2004). Advances in pancreas transplantation.
  35. (2010). Akt and PKC are involved not only in upregulation of telomerase activity but also in cell differentiation-related function via mTORC2 in leukemia cells. Histochemistry and cell biology 134,
  36. (2009). Akt and PTEN: beta-cell mass and pancreas plasticity. Trends in endocrinology and metabolism
  37. (2001). Akt participation in the Wnt signaling pathway through Dishevelled.
  38. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.
  39. (2002). Akt regulates growth by directly phosphorylating
  40. (2008). Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.
  41. (2001). Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice.
  42. (2005). Alternative phospholipase D/mTOR survival signal in human breast cancer cells.
  43. (2001). Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells.
  44. (2009). Amino acid regulation of TOR complex 1. American journal of physiology.Endocrinology and metabolism 296,
  45. (1984). Amino acid sequences of helospectins, new members of the glucagon superfamily, found in Gila monster venom.
  46. (2011). Amino acid signaling to mTOR mediated by inositol polyphosphate multikinase.
  47. (2008). Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell metabolism 7,
  48. (2010). Amino acids activate mTOR complex 2 via PI3K/Akt signalling.
  49. (2005). Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase.
  50. (2002). AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling.
  51. (2011). AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1.
  52. (2008). AMPK phosphorylation of raptor mediates a metabolic checkpoint.
  53. (1992). An array of insulin-activated, proline-directed serine/threonine protein kinases phosphorylate the p70 S6 kinase.
  54. (2009). An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.
  55. (1998). Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3-L1 adipocytes.
  56. (2005). Autophagy in metazoans: cell survival in the land of plenty.
  57. (2010). Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation.
  58. (2011). beta-Catenin activation synergizes with PTEN loss to cause bladder cancer formation.
  59. (2005). beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1.
  60. (2000). Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy.
  61. (2009). Bidirectional transport of amino acids regulates mTOR and autophagy.
  62. (2010). Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis.
  63. (2010). Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling.
  64. (1984). Bilateral primary pigmented nodular adrenocortical disease. Rare cause of the Cushing syndrome.
  65. (2008). Biphasic response of pancreatic {beta} cell mass to ablation of TSC2 in mice. Molecular and cellular biology 28,
  66. (2007). Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb.
  67. (2008). Both Wnt and mTOR signaling pathways are involved in insulin-stimulated proto-oncogene expression in intestinal cells.
  68. (1998). Branched-chain amino acids are essential in the regulation of PHAS-I and p70 S6 kinase by pancreatic beta-cells. A possible role in protein translation and mitogenic signaling.
  69. (1987). Ca2+/calmodulin-dependent phosphorylation of elongation factor 2.
  70. (2011). cAMP inhibits mammalian target of rapamycin complex-1
  71. (2011). cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity.
  72. (2010). cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4. Molecular endocrinology (Baltimore,
  73. (1990). cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes.
  74. (2005). cAMPmediated inhibition of DNA replication and S phase progression: involvement of Rb, p21Cip1, and PCNA.
  75. (2002). Caspase cleavage of initiation factor 4E-binding protein 1 yields a dominant inhibitor of cap-dependent translation and reveals a novel regulatory motif. Molecular and cellular biology 22,
  76. (2008). cdc2-cyclin B regulates eEF2 kinase activity in a cell cycle- and amino acid-dependent manner.
  77. (2000). Cdc42 stimulates RNA splicing via the S6 kinase and a novel S6 kinase target, the nuclear cap-binding complex.
  78. (2001). Cell cycle-dependent phosphorylation of the translational repressor eIF-4E binding protein-1 (4E-BP1).
  79. (2003). Cell cycleregulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B.
  80. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5.
  81. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.
  82. (2009). Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Molecular and cellular biology 29,
  83. (1999). Characterization of S6K2, a novel kinase homologous to S6K1.
  84. (2007). Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.
  85. (2011). Class III PI-3-kinase activates phospholipase D in an amino acid-sensing mTORC1 pathway.
  86. (1990). Cloning of the mitogen-activated S6 kinase from rat liver reveals an enzyme of the second messenger subfamily.
  87. (2011). Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets.
  88. (2008). Common corruption of the mTOR signaling network in human tumors.
  89. (1989). Compensatory growth of pancreatic beta-cells in adult rats after short-term glucose infusion.
  90. (2003). Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade.
  91. (2010). Contribution of human amniotic fluid stem cells to renal tissue formation depends on mTOR. Human molecular genetics 19,
  92. (2002). Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load.
  93. (2004). controls the actin cytoskeleton and is rapamycin insensitive.
  94. (2007). Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth factors (Chur,
  95. (2010). critical factors in mammalian target of rapamycin complex assembly.
  96. (2010). Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.
  97. (2009). Critical roles for the TSC-mTOR pathway in {beta}-cell function. American journal of physiology.Endocrinology and metabolism 297,
  98. (2010). Cyclic AMP controls mTOR through regulation of the dynamic interaction between Rheb and phosphodiesterase 4D. Molecular and cellular biology
  99. (2005). Cyclic AMP inhibition of proliferation of hepatocellular carcinoma cells is mediated by Akt.
  100. (2001). Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1.
  101. (2008). Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation.
  102. (2000). Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Molecular and cellular biology
  103. (2000). Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility.
  104. (2006). Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.
  105. (2010). DAP1, a novel substrate of mTOR, negatively regulates autophagy. Current biology :
  106. (2009). Deconstructing ribosome construction. Trends in biochemical sciences
  107. (2010). Decreased IRS signaling impairs beta-cell cycle progression and survival in transgenic mice overexpressing S6K in beta-cells.
  108. (2008). Defective TGF-beta signaling sensitizes human cancer cells to rapamycin.
  109. (2006). Depletion of type IA regulatory subunit (RIalpha) of protein kinase A (PKA) in mammalian cells and tissues activates mTOR and causes autophagic deficiency. Human molecular genetics
  110. (2009). DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.
  111. (2011). DEPTOR, an mTOR Inhibitor, Is a Physiological Substrate of SCF(betaTrCP)
  112. (2011). Diabetes, cancer, and metformin: connections of metabolism and cell proliferation.
  113. (2011). Diabetes: criteria for the diagnosis and treatment of gestational diabetes mellitus--time for a change. Nature reviews.Endocrinology 7,
  114. (2011). Diabetes: Diabetes mellitus and periodontal disease in youth.
  115. (2010). Diabetes: preventing type 2 diabetes mellitus: is metformin the answer?
  116. (2011). Diabetes: type 1 diabetes mellitus--a door opening to a real therapy?
  117. (2009). Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets.
  118. (2011). Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis.
  119. (2004). Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Molecular and cellular biology 24,
  120. (1998). Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase.
  121. (2008). Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner.
  122. (2004). Dissociation of raptor from mTOR is a mechanism of rapamycininduced inhibition of mTOR function. Genes to cells : devoted to molecular & cellular mechanisms 9,
  123. (2005). Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Molecular and cellular biology 25,
  124. Drosophila S6 kinase: a regulator of cell size.
  125. (2007). Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase.
  126. (1987). eEF2K also undergoes inhibitory phosphorylations on
  127. (2008). Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival.
  128. (1966). Effects of diazoxide on insulin secretion in vitro.
  129. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity?
  130. (2007). Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2.
  131. (2010). Embryoid body formation of human amniotic fluid stem cells depends on mTOR.
  132. (2009). Emerging common themes in regulation of PIKKs and PI3Ks.
  133. (2008). Epac and PKA: a tale of two intracellular cAMP receptors.
  134. (2006). Epac proteins: multi-purpose cAMP targets.
  135. (2011). ERK1/2 phosphorylate Raptor to promote Rasdependent activation of mTOR complex 1 (mTORC1).
  136. (2008). Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling.
  137. (1992). Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines.
  138. (1990). Establishment of a pancreatic beta cell line that retains glucoseinducible insulin secretion: special reference to expression of glucose transporter isoforms.
  139. (2001). Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20.
  140. (2011). Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate.
  141. (1998). Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway.
  142. (1999). Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.
  143. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function.
  144. (2005). Five-year follow-up after clinical islet transplantation.
  145. (2000). FKBP12-rapamycinassociated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions.
  146. (2011). For better or for worse: the role of Pim oncogenes in tumorigenesis.
  147. (1981). Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells.
  148. (2001). FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse.
  149. (2009). Functional interaction of mTOR complexes in regulating mammalian cell size and cell cycle. Human molecular genetics 18,
  150. (2011). G protein-coupled receptors: novel targets for drug discovery in cancer.
  151. (2003). GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR.
  152. (2000). Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin.
  153. (2009). Glucagon acts in a dominant manner to repress insulin-induced mammalian target of rapamycin complex 1 signaling in perfused rat liver. American journal of physiology.Endocrinology and metabolism 297,
  154. (2006). Glucagon and glucagon-like peptide receptors as drug targets. Current pharmaceutical design 12,
  155. (2004). Glucagon represses signaling through the mammalian target of rapamycin in rat liver by activating AMP-activated protein kinase.
  156. (2003). Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor.
  157. (2011). Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic beta-cell mass expansion.
  158. (2008). Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation.
  159. (2001). Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.
  160. (2010). Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression.
  161. (1999). Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS1)-cells.
  162. (2005). Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B.
  163. Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop.
  164. (2004). Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells.
  165. (2010). Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply.
  166. (2006). Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent islets.
  167. (2004). Glucose-stimulated protein synthesis in pancreatic beta-cells parallels an increase in the availability of the translational ternary complex (eIF2-GTP.Met-tRNAi) and the dephosphorylation of eIF2 alpha.
  168. (2012). Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling.
  169. (2011). Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation.
  170. (2009). Glycolytic flux signals to mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of Rheb. Molecular and cellular biology 29,
  171. (2009). Growth control and ribosome biogenesis. Current opinion in cell biology
  172. (2011). GSK-3beta at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways.
  173. Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32. Neuropsychopharmacology : official publication of the
  174. Hierarchical phosphorylation of the translation inhibitor 4E-BP1.
  175. (2002). High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes (review).
  176. (2011). High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex1 and suppressing phosphorylation of 4E-BP1. Cell cycle (Georgetown,
  177. (2010). Human chorionic gonadotropin stimulates theca-interstitial cell proliferation and cell cycle regulatory proteins by a cAMPdependent activation of AKT/mTORC1 signaling pathway. Molecular endocrinology (Baltimore,
  178. (2011). Hydrophobic motif phosphorylation is not required for activation loop phosphorylation of p70 ribosomal protein S6 kinase 1 (S6K1).
  179. (2000). Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice.
  180. (2005). Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors.
  181. (2002). Identification of a conserved motif required for mTOR signaling. Current biology :
  182. (2004). Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase.
  183. (1995). Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycinassociated protein and characterization of a critical serine residue.
  184. (1985). Identification of calmodulin-dependent protein kinase III and its major Mr 100,000 substrate in mammalian tissues.
  185. (2009). Identification of cAMPdependent kinase as a third in vivo ribosomal protein S6 kinase in pancreatic beta-cells.
  186. (2007). Identification of Protor as a novel Rictor-binding component of mTOR complex-2. The Biochemical journal 405,
  187. (2005). Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase.
  188. (2006). Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity.
  189. (1987). Identification of the major Mr 100,000 substrate for calmodulin-dependent protein kinase III in mammalian cells as elongation factor-2.
  190. (1991). Identification of the phosphorylation sites in elongation factor-2 from rabbit reticulocytes.
  191. (2002). Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.
  192. (1986). Identification of yeast mutants with altered telomere structure.
  193. (2011). IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation.
  194. (2007). IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.
  195. (2008). IKKbeta suppression of TSC1 function links the mTOR pathway with insulin resistance.
  196. (2004). In rat hepatocytes glucagon increases mammalian target of rapamycin phosphorylation on serine 2448 but antagonizes the phosphorylation of its downstream targets induced by insulin and amino acids.
  197. (2009). Inactivation of NF-kappaB p50 leads to insulin sensitization in liver through post-translational inhibition of p70S6K.
  198. (2011). Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1.
  199. (2004). Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Current biology :
  200. (2011). Inflammation meets cancer, with NF-kappaB as the matchmaker.
  201. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.
  202. (1991). Inhibition of T and B lymphocyte proliferation by rapamycin.
  203. (2003). Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.
  204. (1998). Insulin mediates glucose-stimulated phosphorylation of PHAS-I by pancreatic beta cells. An insulin-receptor mechanism for autoregulation of protein synthesis by translation.
  205. (2007). Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nature cell biology 9,
  206. (2009). Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway.
  207. (2003). Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
  208. (2000). Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.
  209. (2005). Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the
  210. (2011). Integrity of mTORC2 is dependent on phosphorylation of SIN1 by mTOR.
  211. (2012). Intestinal cell kinase (ICK) promotes activation of mTOR complex 1 (mTORC1) through phosphorylation of Raptor Thr-908.
  212. (1965). Intestinal factors in the control of insulin secretion.
  213. (2006). Islet beta cell failure in type 2 diabetes.
  214. (2000). Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. The New England journal of medicine 343,
  215. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.
  216. (1994). Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.
  217. (2012). L-Leucine Alters Pancreatic beta-Cell Differentiation and Function via the mTor Signaling Pathway.
  218. (2012). Leucyl-tRNA Synthetase Is an Intracellular Leucine Sensor for the mTORC1-Signaling Pathway.
  219. (2003). LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Current biology :
  220. (2003). Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
  221. (2011). Lysosomal positioning coordinates cellular nutrient responses.
  222. (2002). Mammalian cell size is controlled by mTOR and its downstream targets
  223. (2009). Mammalian target of
  224. (2002). Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell death and differentiation 9,
  225. (2009). Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR.
  226. (2010). Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage.
  227. (1999). Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation.
  228. (2011). Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/betacatenin and PTEN.
  229. (2010). Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade.
  230. (2009). Mapping the phosphorylation sites of Ulk1.
  231. (2007). Mechanism for activation of the growth factor-activated AGC kinases by turn motif phosphorylation.
  232. (1999). Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase. Molecular and cellular biology 19,
  233. (2007). Mechanisms of action of glucagon-like peptide 1 in the pancreas.
  234. (2004). Metabolic adaptations to chronic glucose infusion in rats.
  235. (2002). Metabolic and autocrine regulation of the mammalian target of rapamycin by pancreatic beta-cells.
  236. (2002). Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes.
  237. (2010). Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner.
  238. (2009). Mice deficient in ribosomal protein S6 phosphorylation suffer from muscle weakness that reflects a growth defect and energy deficit.
  239. (2010). Mitotic raptor promotes mTORC1 activity, G(2)/M cell cycle progression, and internal ribosome entry site-mediated mRNA translation. Molecular and cellular biology
  240. (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
  241. (1998). Molecular cloning and characterization of a novel p70 S6 kinase, p70 S6 kinase beta containing a proline-rich region.
  242. (2007). Molecular regulation of pancreatic beta-cell mass development, maintenance, and expansion.
  243. (1990). Molecular structure of a major insulin/mitogen-activated 70-kDa S6 protein kinase.
  244. (2006). mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s.
  245. (2009). mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome.
  246. (2005). mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events.
  247. (2010). mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor
  248. (2010). mTOR binds to the promoters of RNA polymerase I- and III-transcribed genes. Cell cycle (Georgetown,
  249. (2008). mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). The Biochemical journal 416,
  250. (2010). mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis.
  251. (2004). mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4EBP1/eukaryotic translation initiation factor 4E. Molecular and cellular biology 24,
  252. (2007). mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex.
  253. (2011). mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends in endocrinology and metabolism
  254. (2011). mTOR Drives Its Own Activation via SCF(betaTrCP)-Dependent Degradation of the mTOR Inhibitor DEPTOR.
  255. (2011). mTOR Generates an Auto-Amplification Loop by Triggering the betaTrCP- and CK1alpha-Dependent Degradation of DEPTOR.
  256. (2008). mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes.
  257. (2002). mTOR interacts with raptor to form a nutrientsensitive complex that signals to the cell growth machinery.
  258. (2004). mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Molecular and cellular biology 24,
  259. (2011). mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. Molecular and cellular biology 31,
  260. (2009). mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging.
  261. (2011). mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry.
  262. (2010). mTOR regulation of autophagy.
  263. (2010). mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.
  264. (2011). mTOR signaling regulates the processing of pre-rRNA in human cells.
  265. (2008). mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation.
  266. (2011). mTOR: from growth signal integration to cancer, diabetes and ageing.
  267. (2005). mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes.
  268. (2009). mTORC1 activation regulates beta-cell mass and proliferation by modulation of cyclin D2 synthesis and stability.
  269. (2010). mTORC1 controls fasting-induced ketogenesis and its modulation by ageing.
  270. (2011). mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H-ATPase.
  271. (2010). mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1alpha.
  272. (2009). mTORC1 signalling and mRNA translation.
  273. (2010). mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4EBPs.
  274. (2010). mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide.
  275. (2010). mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion.
  276. (2000). Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression. Molecular and cellular biology
  277. (1999). Mutational analysis of sites in the translational regulator, PHAS-I, that are selectively phosphorylated by mTOR.
  278. (2010). Network organization of the human autophagy system.
  279. (2004). Neurodegenerative diseases and oxidative stress.
  280. Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner.
  281. (2010). New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1). Cellular signalling 22,
  282. (2009). NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Molecular and cellular biology 29,
  283. (2006). Nfl gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways. Leukemia :
  284. (2008). Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
  285. (2011). Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR.
  286. (2009). Nutrient control of TORC1, a cell-cycle regulator. Trends in cell biology
  287. (2006). Nutrient regulates Tor1 nuclear localization and association with rDNA promoter.
  288. (2008). Nutrient sensing and inflammation in metabolic diseases.
  289. (2011). Nutrient starvation elicits an acute autophagic response mediated by Ulk1 dephosphorylation and its subsequent dissociation from AMPK.
  290. (2009). Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy.
  291. (2009). Nutrient-dependent regulation of autophagy through the target of rapamycin pathway.
  292. (2006). Nutrientdependent multimerization of the mammalian target of rapamycin through the N-terminal HEAT repeat region.
  293. (2008). Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSKmediated raptor phosphorylation.
  294. (2012). Osmotic stress regulates mTOR complex 1 via JNK-mediated Raptor phosphorylation.
  295. (2007). Overview of PDEs and their regulation.
  296. (2011). p62 is a key regulator of nutrient sensing in the mTORC1 pathway.
  297. (2001). p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD.
  298. (2002). Pancreatic beta-cell growth and survival--a role in obesity-linked type 2 diabetes? Trends in molecular medicine 8,
  299. (1998). Pancreatic beta-cell regeneration after 48-h glucose infusion in mildly diabetic rats is not correlated with functional improvement.
  300. (2008). Pathology of an islet transplant 2 years after transplantation: evidence for a nonimmunological loss.
  301. (1969). Paul Langerhans (1847-1888) and his Berlin dissertation (1869). Deutsches medizinisches
  302. (2011). PERK activation at low glucose concentration is mediated by SERCA pump inhibition and confers preemptive cytoprotection to pancreatic beta-cells. Molecular endocrinology (Baltimore,
  303. (1997). PHAS proteins as mediators of the actions of insulin, growth factors and cAMP on protein synthesis and cell proliferation.
  304. (2010). Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway. American journal of physiology.Cell physiology 299,
  305. (2001). Phosphatidic acid-mediated mitogenic activation of mTOR signaling.
  306. (2005). Phosphatidylinositol 3-kinase-Akt pathway plays a critical role in early cardiomyogenesis by regulating canonical Wnt signaling.
  307. (2002). Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin.
  308. (2003). Phospholipase D confers rapamycin resistance in human breast cancer cells.
  309. (2011). Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1).
  310. (2008). Phospholipase D1 is an effector of Rheb in the mTOR pathway.
  311. (2011). Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling.
  312. (1998). Phosphorylation and activation of p70s6k by PDK1.
  313. (2005). Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.
  314. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.
  315. (1988). Phosphorylation of elongation factor 2 by EF-2 kinase affects rate of translation.
  316. (2004). Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases.
  317. (2005). Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase.
  318. (2011). Phosphorylation of Raptor by p38beta participates in arsenite-induced mammalian target of rapamycin complex 1 (mTORC1) activation.
  319. (1988). Phosphorylation of the elongation factor 2: the fifth Ca2+/calmodulin-dependent system of protein phosphorylation.
  320. (1997). Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin.
  321. (2011). Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy.
  322. (2009). PIKKing on PKB: regulation of PKB activity by phosphorylation. Current opinion in cell biology
  323. (2009). PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells.
  324. (2010). PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis.
  325. (2008). PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival.
  326. (2006). PML inhibits HIF1alpha translation and neoangiogenesis through repression of mTOR.
  327. (1994). Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogeninduced gene expression.
  328. (2010). PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR.
  329. (2007). PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis.
  330. (2007). PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex.
  331. (2007). PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase.
  332. (2007). PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding.
  333. (2008). Pre-mRNA splicing: a complex picture in higher definition. Trends in biochemical sciences
  334. (2003). Prevention strategies for type 1 diabetes mellitus: current status and future directions. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 17,
  335. (2006). Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.
  336. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation.
  337. (2005). Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
  338. (2011). Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. The Biochemical journal 436,
  339. (2012). Protor-2 interacts with tristetraprolin to regulate mRNA stability during stress.
  340. (2010). Rab-family GTPase regulates TOR complex 2 signaling in fission yeast. Current biology :
  341. (1994). RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.
  342. (2010). Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids.
  343. (1999). Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
  344. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
  345. (2003). Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets.
  346. (2010). Rapamycin impairs metabolism-secretion coupling in rat pancreatic islets by suppressing carbohydrate metabolism.
  347. (2001). Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. American journal of physiology.Renal physiology
  348. (2009). Rapamycin induces transactivation of the EGFR and increases cell survival.
  349. (2009). Rapamycin inhibits mTORC1, but not completely.
  350. (2008). Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells.
  351. (2011). Rapamycin passes the torch: a new generation of mTOR inhibitors.
  352. (2003). Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression.
  353. (2012). Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2). Diabetologia 55(5):1355-1365,
  354. (1992). Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases.
  355. (1997). Rapamycin-induced apoptosis is p53-independent in human prostate carcinoma PC-3 cells.
  356. (2012). Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity.
  357. (1995). Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells.
  358. (2011). Raptor and Rheb negatively regulate skeletal myogenesis through suppression of insulin receptor substrate 1 (IRS1).
  359. (2002). Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.
  360. (2007). RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation.
  361. (2008). Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling.
  362. (2011). Reactive oxygen species and insulin resistance: the good, the bad and the ugly. Trends in pharmacological sciences
  363. (2011). Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway.
  364. (2012). Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks.
  365. (2009). Regulation and localization of ribosomal protein S6 kinase 1 isoforms. Growth factors (Chur,
  366. (2009). Regulation mechanisms and signaling pathways of autophagy.
  367. (1999). Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism.
  368. (2006). Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP.
  369. (1998). Regulation of cell death protease caspase-9 by phosphorylation.
  370. (2000). Regulation of cellular growth by the Drosophila target of rapamycin dTOR.
  371. (2008). Regulation of DNA synthesis in mouse embryonic stem cells by transforming growth factor-alpha: involvement of the PI3-K/Akt and Notch/Wnt signaling pathways. Growth factors (Chur,
  372. (2001). Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase.
  373. (1993). Regulation of elongation factor-2 by multisite phosphorylation.
  374. (2002). Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Molecular and cellular biology 22,
  375. (2007). Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha.
  376. (2005). Regulation of mTOR and cell growth in response to energy stress by REDD1. Molecular and cellular biology 25,
  377. (2010). Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation.
  378. (2004). Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.
  379. (2009). Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Molecular and cellular biology 29,
  380. (2010). Regulation of mTORC1 by the Rab and Arf GTPases.
  381. (2011). Regulation of mTORC1 complex assembly and signaling by GRp58/ERp57. Molecular and cellular biology 31,
  382. (2005). Regulation of pancreatic beta-cell mass.
  383. (2008). Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation.
  384. (2011). Regulation of ribosomal protein S6 phosphorylation by casein kinase 1 and protein phosphatase 1. The Journal of biological chemistry
  385. (2011). Regulation of TFEB and V-ATPases by mTORC1.
  386. (1989). Regulation of the biosynthesis of insulin-secretory-granule proteins. Co-ordinate translational control is exerted on some, but not all, granule matrix constituents.
  387. (2010). Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress.
  388. (1998). Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies.
  389. (2008). Regulation of TORC1 by Rag GTPases in nutrient response.
  390. (2009). Regulation of translation initiation in eukaryotes: mechanisms and biological targets.
  391. (1995). Repression of capdependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E.
  392. (2010). Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells.
  393. (2011). Resistance to type 2 diabetes mellitus: a matter of hormesis?
  394. (2007). Rheb activates mTOR by antagonizing its endogenous inhibitor,
  395. (2003). Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.
  396. (2003). Rheb promotes cell growth as a component of the insulin/TOR signalling network.
  397. (2011). Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia.
  398. (2005). Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis.
  399. (2006). Ribosomal protein S6 phosphorylation: from protein synthesis to cell size.
  400. (2006). Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases.
  401. (2010). Ribosome biogenesis: from structure to dynamics. International review of cell and molecular biology 284,
  402. (2010). Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction.
  403. (2010). Rictor is a novel target of p70 S6 kinase-1.
  404. (2010). Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. Molecular cancer research :
  405. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.
  406. (2009). Rictor/TORC2 regulates Caenorhabditis elegans fat storage, body size, and development through sgk-1. PLoS biology 7,
  407. (2009). Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans.
  408. (2001). Role of AMP-activated protein kinase in mechanism of metformin action.
  409. (2012). Role of AMPK-mTORUlk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks. Molecular and cellular biology 32,
  410. (2010). Role of the TSC1-TSC2 complex in the integration of insulin and glucose signaling involved in pancreatic beta-cell proliferation.
  411. (2007). ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nature reviews.Molecular cell biology 8,
  412. (2009). S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation.
  413. (2008). S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2.
  414. (2010). S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response.
  415. (2008). S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade.
  416. (2006). S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt.
  417. (2007). S6K1-mediated disassembly of mitochondrial URI/PP1gamma complexes activates a negative feedback program that counters S6K1 survival signaling.
  418. (2004). S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Molecular and cellular biology 24,
  419. (2000). Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR.
  420. (2003). Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta.
  421. (2011). Signaling by Phorbol Esters.
  422. (2004). Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets.
  423. (2007). Signalling to translation: how signal transduction pathways control the protein synthetic machinery.
  424. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity.
  425. (2006). Sirolimus is associated with reduced islet engraftment and impaired beta-cell function.
  426. (2009). Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Molecular and cellular biology 29,
  427. (2004). SKAR is a specific target of S6 kinase 1 in cell growth control.
  428. (2008). SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs.
  429. (2011). Spatial coupling of mTOR and autophagy augments secretory phenotypes.
  430. Specific and combined effects of insulin and glucose on functional pancreatic beta-cell mass in vivo in adult rats.
  431. (2008). SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth.
  432. (1995). Structural and functional analysis of pp70S6k.
  433. (2010). Structure of the human mTOR complex I and its implications for rapamycin inhibition.
  434. (2008). Suppression of programmed cell death 4 (PDCD4) protein expression by BCRABL-regulated engagement of the mTOR/p70 S6 kinase pathway.
  435. (2011). Synaptic stimulation of mTOR is mediated by Wnt signaling and regulation of glycogen synthetase kinase-3.
  436. (2008). Syndecan-4 regulates subcellular localization of mTOR Complex2 and Akt activation in a PKCalphadependent manner in endothelial cells.
  437. (2010). Systemic inflammation as a confounding factor in cancer biomarker discovery and validation.
  438. (2009). Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
  439. (2009). Targeting cancer cells by ROSmediated mechanisms: a radical therapeutic approach? Nature reviews.Drug discovery 8,
  440. (2010). Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy.
  441. (2011). Targets Akt for Proteasomal Degradation via Phosphorylation at the Hydrophobic Motif.
  442. (1991). Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.
  443. (2007). Tel2 regulates the stability of PI3K-related protein kinases.
  444. (2010). Termination of autophagy and reformation of lysosomes regulated by mTOR.
  445. (1998). The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?
  446. (2002). The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotideindependent mechanism.
  447. (2000). The cAMP signaling pathway as a therapeutic target in lymphoid malignancies.
  448. (1979). The effect of glucose-, arginine- and leucine-deprivation on mouse blastocyst outgrowth in vitro.
  449. (1993). The efficacy and toxicity of rapamycin in murine islet transplantation. In vitro and in vivo studies.
  450. (2002). The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites.
  451. (1990). The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21.
  452. (2007). The gene encoding the splicing factor SF2/ASF is a proto-oncogene.
  453. (1993). The Huntington's Disease Collaborative Research Group.
  454. (1999). The hydrophobic phosphorylation motif of conventional protein kinase C is regulated by autophosphorylation. Current biology :
  455. (2011). The identification of raptor as a substrate for p44/42 MAPK.
  456. (1986). The inositol tris/tetrakisphosphate pathway--demonstration of Ins(1,4,5)P3 3-kinase activity in animal tissues.
  457. (2011). The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.
  458. (2003). The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif.
  459. (2006). The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity.
  460. (2008). The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C.
  461. (2010). The mechanism of eukaryotic translation initiation and principles of its regulation.
  462. (2004). The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. American journal of physiology.Cell physiology
  463. (2006). The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity.
  464. (2011). The mTORregulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.
  465. (2010). The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal 1365.
  466. (2005). The NF1 tumor suppressor critically regulates TSC2 and mTOR.
  467. (2010). The nuts and bolts of AGC protein kinases. Nature reviews.Molecular cell biology
  468. (2009). The pharmacology of mTOR inhibition.
  469. (2007). The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1.
  470. (2008). The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science
  471. (2011). The ribosome as a molecular machine: the mechanism of tRNA-mRNA movement in translocation.
  472. (2000). The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Current biology :
  473. (2007). The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells.
  474. (2009). The role of inflammation in insulitis and beta-cell loss in type 1 diabetes.
  475. (2012). The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes. Cellular and Molecular Life Sciences 69(8):1289-1304,
  476. (2006). The Saccharomyces cerevisiae Lipin homolog is a Mg2+-dependent phosphatidate phosphatase enzyme.
  477. (2011). The serine/threonine kinase ULK1 is a target of multiple phosphorylation events.
  478. (2001). The translational inhibitor 4E-BP is an effector of PI(3)K/Akt signalling and cell growth in Drosophila.
  479. (2012). The translational landscape of mTOR signalling steers cancer initiation and metastasis.
  480. (2004). The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.
  481. (2008). The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Molecular and cellular biology 28,
  482. (2008). The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.
  483. (2005). The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.
  484. (2002). The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells.
  485. (2011). The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives.
  486. (2010). The year in G protein-coupled receptor research. Molecular endocrinology (Baltimore,
  487. (2004). Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status.
  488. (1990). Three phosphorylation sites in elongation factor 2. FEBS letters 275,
  489. (2012). to Regulate Phosphorylation of Akt.
  490. (2002). TOR deficiency in C. elegans causes developmental arrest and intestinal atrophy by inhibition of mRNA translation. Current biology :
  491. (2009). TORC1 association with rDNA chromatin as a mechanism to co-regulate Pol I and Pol III. Cell cycle (Georgetown,
  492. (2008). TORC1 is essential for NF1-associated malignancies. Current biology :
  493. (2003). TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Current biology :
  494. (2006). Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass.
  495. (2000). Transplantation of the islets of Langerhans: new hope for treatment of type 1 diabetes mellitus. Trends in endocrinology and metabolism:
  496. (2002). Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling.
  497. (2006). TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.
  498. (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.
  499. (2003). TSC2 mediates cellular energy response to control cell growth and survival.
  500. (2002). Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).
  501. (2002). Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
  502. (2004). Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
  503. (2009). Tumour necrosis factor and cancer.
  504. (2011). TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1.
  505. (2011). Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy.
  506. (2011). Type 2 diabetes as an inflammatory disease.
  507. (1998). Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia.
  508. (2009). ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery.
  509. (2011). Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory feedback loop.
  510. (2009). ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy.
  511. (2010). Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends in biochemical sciences
  512. (2011). Understanding type 1 diabetes through genetics: advances and prospects.
  513. (2009). Upregulation of the mammalian target of rapamycin complex 1 pathway by Ras homolog enriched in brain in pancreatic beta-cells leads to increased beta-cell mass and prevention of hyperglycemia.
  514. (2004). WNT and beta-catenin signalling: diseases and therapies.
  515. (2005). Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT.
  516. (2008). Wnt signalling and its impact on development and cancer.
  517. (2008). WNT signalling in the immune system: WNT is spreading its wings.
  518. (2011). Wnt7a-Fzd7 signalling directly activates the Akt/mTOR anabolic growth pathway in skeletal muscle.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.